Medical cannabis therapy can significantly reduce chronic pain in patients aged 65 and older without adverse effects, researchers at Ben-Gurion University of the Negev (BGU) and the Cannabis Clinical Research Institute at Soroka University Medical Center.
The new study, published in The European Journal of Internal Medicine, found cannabis therapy to be safe and effective for elderly patients who are seeking to address cancer symptoms, Parkinson’s disease, post-traumatic stress disorder, ulcerative colitis, Crohn’s disease, multiple sclerosis, and other medical issues.
“While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,” says Prof. Victor Novack, a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Cannabis Clinical Research Institute at Soroka.
“After monitoring patients 65 and older for six months, we found medical cannabis treatment significantly relieves pain and improves quality of life for seniors with minimal side effects reported.”
This older population represents a growing segment of medical cannabis users, ranging from approximately seven percent to more than 33 percent, depending on the country. Recent US polls indicate Americans over 65 represent 14 percent of the total population and use more than 30 percent of all prescription drugs, including highly addictive painkillers.
BGU researchers surveyed 2,736 patients 65 years and older who received medical cannabis through Tikun Olam, Israel’s largest medical cannabis supplier. More than 60 percent were prescribed medical cannabis due to pain, particularly pain associated with cancer. After six months of treatment, more than 93% of respondents reported their pain dropped from a median of eight to four on a 10-point scale. Close to 60 percent of patients who originally reported “bad” or “very bad” quality of life upgraded to “good” or “very good” after six months. More than 70 percent of patients surveyed reported moderate to significant improvement in their condition.
The most commonly reported adverse effects were dizziness (9.7 percent) and dry mouth (7.1 percent). After six months, more than 18 percent of patients surveyed had stopped using opioid analgesics or had reduced their dosage.
While the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.
The researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of “Tikun Olam,” and Prof. Raphael Mechoulam of Hebrew University.
By: Yona Schnitzer
New York City News2 days ago
Principal at NY Jewish Day School Arrested for Production of Child Porn
Israel News3 weeks ago
Netanyahu: Hezbollah Attack Caused ‘No Casualties, Not Even a Scratch’
Arts & Culture2 weeks ago
“Our Boys”: The HBO Series Uses a Jewish Tragedy to Condemn Israeli Society
New York City News2 weeks ago
Drama Surrounds Serena Williams’ Bid for Grand Slam Title at US Open
News4 days ago
Israel Needs Netanyahu More than Netanyahu Needs Israel
National News2 weeks ago
CEO of Wholesale Ticket Business Pleads Guilty To Running Multimillion-Dollar Ponzi Scheme
National News2 weeks ago
Revealed: US Army’s Devastating Answer to Iran’s Centrifuges at Nuke Facility
International latest news2 weeks ago
British Jewish Newspaper Buckles to Hamas